This new approach of considering RUNX2/HIF-1α as an integral transcription factor in osteosarcoma may aid in mitigating tumour development, improving treatment resistance, and accelerating the overall survival rate of patients with osteosarcoma. This evidence concerns the gene RUNX2 and osteosarcoma.